Singapore markets closed

Summit Therapeutics Inc. (SMMT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.22+0.54 (+6.15%)
As of 10:05AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close8.69
Open9.84
Bid8.75 x 500
Ask9.24 x 500
Day's range8.83 - 9.94
52-week range1.52 - 11.25
Volume9,862,488
Avg. volume3,555,577
Market cap6.472B
Beta (5Y monthly)-1.13
PE ratio (TTM)24.26
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Benzinga

    Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study

    On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre

  • Barrons.com

    Competitor to Merck's Keytruda Worries Some Investors

    Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients.

  • Insider Monkey

    Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript

    Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […]